Direct Answer
Managed care organizations (MCOs) earn revenue from insurance premiums and manage healthcare costs by negotiating provider rates, managing utilization (what medical services are approved), and operating care management programs. UnitedHealth Group, Humana, Cigna Group, Elevance Health (formerly Anthem), and CVS Health (through Aetna) are the dominant US managed care companies. Medicare Advantage (government-subsidized private Medicare plans) has been the key growth driver for the sector for a decade, but rising medical costs strained results in 2024-2025.
MCO Business Model: Premiums, Medical Loss Ratio, and Margin
The core MCO business model is straightforward: collect premiums from members (individuals, employers, government programs), pay medical claims, and retain the difference as margin after operating expenses. The key financial metric is the medical loss ratio (MLR): the percentage of premium revenue paid out as medical claims. A 85% MLR means 85 cents of every premium dollar goes to medical costs; the remaining 15 cents covers SG&A (selling, general and administrative expenses), administrative costs, and pretax profit.
Federal regulations under the Affordable Care Act mandate minimum MLRs: 85% for large group insurance (employer-sponsored plans), 80% for small group and individual market plans. If an insurer's MLR falls below the required threshold, they must rebate the excess to members. This regulatory floor prevents MCOs from simply charging high premiums and pocketing the difference -- but it also means that MLR management (keeping it near the required minimum without exceeding it) is the central operational challenge of the business.
The MCO's value comes from its ability to manage medical costs below the actuarially expected level at the time premiums are set. MCOs negotiate discounts with hospitals, physicians, and pharmacy benefit managers; implement utilization management (prior authorization, step therapy, disease management programs) that reduces unnecessary or lower-value care; and deploy predictive analytics to identify high-risk members who benefit from proactive care management programs. An MCO that successfully manages costs to 82% MLR on a 85% mandate keeps a 3-point margin advantage -- at scale (UnitedHealth collects $300+ billion in annual premium revenue), this is several billion dollars in annual pre-tax earnings.
Medicare Advantage: The Decade-Long Growth Engine
Medicare Advantage (MA) is the private insurance alternative to traditional fee-for-service Medicare. Seniors eligible for Medicare (age 65+, or disabled) can choose to receive their Medicare benefits through a private MCO's plan (MA) rather than directly through CMS's traditional Medicare program. The MCO receives a risk-adjusted premium from CMS (Centers for Medicare & Medicaid Services) based on the member's health status; the MCO then covers the member's medical costs using its provider network and utilization management capabilities.
MA grew from approximately 13% of Medicare beneficiaries in 2005 to 50%+ of Medicare beneficiaries by 2024 -- roughly 32 million members -- driven by better supplemental benefits (dental, vision, hearing, fitness), lower or zero out-of-pocket costs versus traditional Medicare, and more coordinated care coordination features. This growth made MA the single largest MCO market segment and the primary driver of MCO revenue and earnings growth for the past decade.
The MA economics became severely strained in 2024-2025: medical cost trends (utilization, particularly high-cost procedures deferred during COVID, and rising specialty drug costs) significantly exceeded CMS's premium rate adjustments, causing several MCOs' MA medical loss ratios to exceed 90%+ (versus historical 85-87%). Humana (most concentrated in MA among major MCOs) suffered the most severe earnings impact; UnitedHealth Group, with MA as a significant but not dominant revenue source, had better diversification cushion.
UnitedHealth Group: Scale, Optum, and Vertical Integration
UnitedHealth Group (UNH) is the largest US health insurer by revenue ($370+ billion annually) and market capitalization, distinguished by its Optum segment which provides pharmacy benefit management (OptumRx), health services (OptumHealth care delivery sites, behavioral health, home care), and health technology (OptumInsight data and analytics). This vertical integration differentiates UnitedHealth from pure MCOs: approximately 40% of its revenue comes from Optum rather than UnitedHealthcare insurance premiums, and Optum's higher margins and faster growth support premium valuation multiples.
The logic of UnitedHealth's vertical integration: an MCO that also operates the pharmacy benefit manager, specialty pharmacy, and home health services can optimize cost and quality across the care continuum rather than relying on third-party service providers at arm's-length prices. When OptumRx manages a member's pharmacy benefits under UnitedHealthcare's insurance plan, the MCO's clinical data and the pharmacy's dispensing data combine, enabling more sophisticated drug management, cost control, and clinical programs than either could achieve separately. This integrated data advantage becomes more valuable as claims data analytics drive care management.
Policy and Regulatory Risk: The Dominant Investment Risk in MCOs
MCO businesses operate under continuous government pricing, coverage, and regulatory decisions that can significantly affect profitability without any change in operational performance. The two largest regulatory risks are CMS Medicare Advantage rate decisions (annually, CMS announces the benchmark payment rates and risk adjustment parameters for MA plans for the coming year -- a decision that directly determines whether MCOs earn acceptable margins in their MA books) and potential congressional action on healthcare reform (expansion or contraction of government health programs, drug pricing legislation, insurance market rule changes).
The 2024-2025 MA earnings pressure was partly regulatory: CMS's risk adjustment methodology changes (reducing payments for certain diagnosis codes, following scrutiny of MCOs' upcoding practices) combined with higher-than-expected medical cost trends created a double squeeze. MCOs argued that CMS rate adjustments were insufficient to cover actual cost trends; CMS was simultaneously scrutinizing MA risk adjustment practices through audits and regulatory enforcement. The combination made 2024-2025 the worst MA earnings environment in over a decade.
Commercial insurance (employer-sponsored insurance) faces its own regulatory risks: ACA employer mandate provisions, state-level insurance regulation, and network adequacy requirements. But commercial insurance is more buffered from single regulatory decisions than MA because pricing is negotiated between MCOs and employers (subject to market competition), not set by a government agency.
PBM Integration: Pharmacy Benefit Managers as MCO Subsidiaries
The three largest pharmacy benefit managers (PBMs) are now subsidiaries of major MCOs: Express Scripts (Cigna/Evernorth), Caremark (CVS Health/Aetna), and OptumRx (UnitedHealth). PBMs administer prescription drug benefits for health plan members, negotiate rebates from pharmaceutical manufacturers, operate mail-order pharmacies, and manage specialty pharmacy (high-cost biologics, gene therapies, oncology drugs). The MCO-PBM integration allows these companies to manage total healthcare costs (medical + pharmacy) in a coordinated way rather than separately.
PBM economics generate ongoing controversy: PBMs negotiate large rebates from pharmaceutical manufacturers based on formulary placement (choosing to include or exclude a drug from the plan's covered drug list is enormous leverage over manufacturers), but critics argue these rebates are not fully passed through to plan members and represent a form of hidden compensation that increases rather than decreases drug costs. Federal legislation (the Inflation Reduction Act's Medicare drug negotiation provisions, ongoing pharmacy rebate reform proposals) directly affects PBM economics. CVS Health and Cigna's Evernorth both operate "pass-through" PBM models that explicitly pass 100% of rebates to plan sponsors as an alternative to the traditional retained-rebate model.
FAQ
What is a medical loss ratio and why does it matter for MCO investing?
The medical loss ratio (MLR) is the percentage of premium revenue paid out as medical claims. An MCO with an 86% MLR paid 86 cents of every premium dollar on medical costs, retaining 14 cents to cover operating expenses and earn profit. Federal law mandates minimum MLRs (80% for small group/individual, 85% for large group) -- MCOs that fall below must rebate excess to members. For investors, the MLR is the most critical line in an MCO's financials: a 1-point increase (from 85% to 86%) on $100 billion in premium revenue is a $1 billion reduction in gross profit. MCO stocks are highly sensitive to MLR trend signals because the leverage is enormous -- a medical cost trend 200 basis points above pricing assumptions can cut earnings by 15-30% in a given year. This is why MCO stocks often move sharply on any indication of higher-than-expected utilization trends (outpatient procedure surges, drug cost acceleration, flu season severity), and why actuarial forecasting capability is a genuine competitive advantage for MCOs that consistently price accurately.
How does Medicare Advantage work and why was it so profitable before 2024?
Medicare Advantage (MA) allows Medicare-eligible seniors to receive their Medicare benefits through a private health plan offered by an MCO. CMS pays the MCO a risk-adjusted premium (adjusted for the member's health status so sicker members generate higher payments) and the MCO manages the member's medical costs using its provider network, formulary, and care management programs. MA was extremely profitable for MCOs for most of the 2010s-2023 period because: MCOs successfully negotiated provider rates significantly below traditional Medicare fee-for-service rates (traditional Medicare pays published fee schedules; MCOs negotiate typically 70-85% of Medicare rates, though this varies by market); risk coding practices (documenting all of a member's diagnoses to maximize risk-adjusted payments) created payments above actual medical cost trends; supplemental benefits (dental, vision, fitness) attracted healthier-than-average enrollees who generated below-average medical costs; and CMS rate increases generally tracked or exceeded medical cost trends during this period. Beginning in 2024, this calculus shifted: deferred utilization returned (procedures delayed during COVID were completed), specialty drug costs accelerated, and CMS's risk adjustment methodology changes reduced payments -- creating the first sustained MA margin compression in over a decade.
What is the difference between UnitedHealth, Humana, Cigna, and Elevance Health?
The four major publicly traded US MCOs have meaningfully different business mixes and market focuses. UnitedHealth Group is the most diversified -- its Optum segment (pharmacy benefits, health services, data analytics) contributes 40%+ of revenue and higher margins than insurance alone; its insurance segment covers commercial, Medicare Advantage, Medicaid, and international markets. Humana is the most Medicare Advantage-concentrated of the large MCOs (80%+ of its medical membership is MA), making it the most sensitive to MA regulatory and medical cost trends. Cigna Group operates primarily in commercial employer-sponsored insurance and its large Evernorth health services segment (Express Scripts PBM, specialty pharmacy, behavioral health) -- Cigna sold its MA and Medicare Supplement businesses to HCSC in 2022-2024, exiting government health care to focus on commercial and pharmacy. Elevance Health (formerly Anthem) is the largest BCBS (Blue Cross Blue Shield) licensee, with strong commercial market positions across multiple states and growing Medicare Advantage and Medicaid managed care. Its CarelonRx PBM (rebranded from IngenioRx) provides pharmacy benefit capabilities integrated with its commercial plans.
Why are MCO stocks considered defensive investments?
MCO stocks have traditionally been considered relatively defensive because healthcare demand (medical claims) is less sensitive to economic cycles than discretionary consumer spending -- people need medical care regardless of whether the economy is expanding or contracting, and employer-sponsored insurance enrollment tends to remain stable even as workers' incomes vary. The revenue base is contractual (multi-year employer insurance contracts, government MA and Medicaid contracts) with predictable premium cash flows. However, "defensive" is relative: MCO stocks are highly sensitive to regulatory/policy risk (healthcare reform, CMS rate decisions), medical cost trend surprises, and pandemic-related utilization anomalies. They are defensive compared to cyclical industrials or consumer discretionary companies, but face their own form of binary regulatory risk that can produce sharp earnings revisions independent of economic conditions. The 2024-2025 period illustrated this: MCO stocks fell 20-40% not due to economic recession but due to medical cost trend surprises and Medicare Advantage regulatory changes -- risks that have no direct analog in other "defensive" sectors like utilities or consumer staples.